BioSight
Companies
Stoke Therapeutics, Inc. logo

STOK

NASDAQBEDFORD, MA
Stoke Therapeutics, Inc.

Stoke Therapeutics is a clinical-stage biotechnology company developing antisense oligonucleotide therapies for rare neurological diseases, with its lead program zorevunersen (STK-001) in clinical development for Dravet syndrome. The company has a collaboration agreement with Biogen that includes potential milestone and royalty payments, and is focused on addressing underlying causes of seizure disorders through its proprietary modality.

Price history not yet available for STOK.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar